Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01042925 | Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | completed | Phase 1 / Phase 2 | 42 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT01082068 | Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer | completed | Phase 1 / Phase 2 | 72 | SanofiINDUSTRY | 3 | Jun 3, 2016 | clinicaltrials |
| NCT00193180 | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT01201265 | A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 1 | May 27, 2016 | clinicaltrials |
| NCT00754325 | Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor | completed | Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 1 | May 26, 2016 | clinicaltrials |
| NCT00664781 | Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | completed | Phase 2 | 78 | Cancer Research UKOTHER | 1 | May 24, 2016 | clinicaltrials |
| NCT01431196 | Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer | completed | Phase 2 | 29 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | May 19, 2016 | clinicaltrials |
| NCT00327743 | Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 34 | SanofiINDUSTRY | 2 | May 18, 2016 | clinicaltrials |
| NCT00203502 | Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer | completed | Phase 2 | 40 | University of ArkansasOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00387907 | Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer | completed | Phase 2 | 6 | SanofiINDUSTRY | 1 | May 5, 2016 | clinicaltrials |
| NCT00903162 | Extended Endocrine Therapy for Premenopausal Women With Breast Cancer | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01763710 | Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer(neurabrax) | completed | Phase 2 | 60 | Fundacion OncosurNETWORK | 1 | Mar 29, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01941407 | First Line Metastatic Breast Cancer Treatment (ESMERALDA)(ESMERALDA) | completed | Phase 2 | 61 | ARCAGY/ GINECO GROUPOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT00010010 | Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer | completed | Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00012129 | Chemotherapy in Treating Patients With Breast Cancer | completed | Phase 1 / Phase 2 | — | NYU Langone HealthOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00370552 | A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer | completed | Phase 2 | 136 | R-PharmINDUSTRY | 5 | Mar 10, 2016 | clinicaltrials |
| NCT00490646 | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer | completed | Phase 2 | 50 | R-PharmINDUSTRY | 5 | Mar 10, 2016 | clinicaltrials |
| NCT00593827 | Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer | completed | Phase 2 | 176 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00084539 | Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer | completed | Phase 2 | 78 | Fox Chase Cancer CenterOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT02523417 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | completed | Phase 2 | 384 | Bristol-Myers SquibbINDUSTRY | 15 | Feb 24, 2016 | clinicaltrials |
| NCT01205503 | Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release | completed | Phase 2 | 32 | Mara ChambersOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT00587964 | Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00917735 | Green Tea and Reduction of Breast Cancer Risk | completed | Phase 2 | 1,075 | University of MinnesotaOTHER | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00054275 | Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer | completed | Phase 2 | 39 | Paula Silverman, MDOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01204437 | Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast(ICE-II) | completed | Phase 2 / Phase 3 | 400 | GBG Forschungs GmbHOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01972984 | Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients(NEO ER 11-05) | completed | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01948128 | Effects of Vitamin D in Patients With Breast Cancer(OTT 12-06) | completed | Phase 2 | 83 | Ottawa Hospital Research InstituteOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT02041351 | Biweekly Docetaxel in Patients With Metastatic Breast Cancer. | completed | Phase 2 | 17 | Centro Universitario contra el CáncerOTHER | 1 | Jan 27, 2016 | clinicaltrials |
| NCT00468585 | Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model | completed | Phase 1 / Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00769470 | Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 18 | Translational Oncology Research InternationalOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00193089 | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 0 | Dec 10, 2015 | clinicaltrials |
| NCT00216021 | Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | completed | Phase 2 | 25 | Hoosier Cancer Research NetworkOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT00244881 | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00899574 | Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases | completed | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00429507 | Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases | completed | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00571987 | Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation(eRFA) | completed | Phase 1 / Phase 2 | 107 | University of ArkansasOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00693719 | Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer | completed | Phase 2 | 31 | University of ArizonaOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00741039 | Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | completed | Phase 2 | 126 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01273896 | Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer | completed | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT01832051 | Clinical Value of 89Zr-trastuzumab PET | completed | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Nov 5, 2015 | clinicaltrials |
| NCT00773344 | Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin | completed | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 4, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Jun 3, 2016source: clinicaltrials